<table id="table3" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 3	Established and Other Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or on Predicted Interaction with INVIRASE/ritonavir</caption>
<col align="left" valign="top" width="25%"></col>
<col align="left" valign="top" width="25%"></col>
<col align="left" valign="top" width="50%"></col>
<thead>
<tr>
<th align="center" stylecode="Lrule Rrule">Concomitant Drug Class:<br/>												Drug Name 											</th>
<th align="center" stylecode="Rrule">Effect on  Concentration of Saquinavir or Concomitant Drug</th>
<th align="center" stylecode="Rrule">Clinical Comment</th>
</tr>
</thead>
<tbody>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">HIV-1 Antiviral Agents</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Non-nucleoside reverse transcriptase inhibitor:</content>
<br/>Delavirdine<footnote id="tb3ft2">INVIRASE/ritonavir interaction has not been evaluated.</footnote>
<br/>
</td>
<td stylecode="Rrule">↑ Saquinavir<br/>
<br/>Effect on delavirdine is not well established</td>
<td stylecode="Rrule">Appropriate doses of the combination with respect to safety and efficacy have not been established. Coadministration is not recommended.<br/>Liver function should be monitored frequently if this combination is prescribed.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Non-nucleoside reverse transcriptase inhibitor:</content>
<br/>Efavirenz<footnote id="tb3ft1">See <content stylecode="bold">
<linkhtml href="#table6">Pharmacokinetics, Drug Interactions (12.3), Table 6</linkhtml>
</content> and <content stylecode="bold">
<linkhtml href="#table7">Table 7</linkhtml>
</content> for magnitude of interactions.</footnote>,<br/>nevirapine<footnoteref idref="tb3ft2"></footnoteref>
</td>
<td stylecode="Rrule">↓ Saquinavir<br/>↔ Efavirenz<br/>
<br/>
<br/>
</td>
<td stylecode="Rrule">Appropriate doses of the combination of efavirenz or nevirapine and INVIRASE/ritonavir with respect to safety and efficacy have not been established. Coadministration is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">HIV-1 protease inhibitor:</content>
<br/>Indinavir<footnoteref idref="tb3ft2"></footnoteref>
</td>
<td stylecode="Rrule">↑ Saquinavir<br/>↑ Indinavir</td>
<td stylecode="Rrule">Appropriate doses of the combination of indinavir and INVIRASE/ritonavir with respect to safety and efficacy have not been established. Coadministration is not recommended.<br/>Increased concentrations of indinavir may result in nephrolithiasis. For further details see complete prescribing information for Crixivan<sup>®</sup> (indinavir).</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">HIV-1 protease inhibitor:</content>
<br/>Lopinavir/ritonavir<footnoteref idref="tb3ft1"></footnoteref> (coformulated tablet)</td>
<td stylecode="Rrule">↔ Saquinavir<br/>↔ Lopinavir<br/>↓ Ritonavir<br/>
</td>
<td stylecode="Rrule">Evidence from several clinical trials indicates that saquinavir concentrations achieved with the saquinavir and lopinavir/ritonavir combination are similar to those achieved following INVIRASE/ritonavir 1000/100 mg.  The recommended dose for this combination is INVIRASE 1000 mg plus lopinavir/ritonavir 400/100 mg bid.<br/>
<br/>Lopinavir/ritonavir in combination with INVIRASE should be used with caution. Additive effects on QT and/or PR interval prolongation may occur with INVIRASE <content stylecode="italics">[see <linkhtml href="#S5.2">Warnings and Precautions (5.2,</linkhtml>
<linkhtml href="#S5.3"> 5.3)</linkhtml>]. </content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">HIV-1 protease inhibitor:</content>
<br/>Nelfinavir<footnoteref idref="tb3ft1"></footnoteref>
</td>
<td stylecode="Rrule">↑ Saquinavir<br/>
</td>
<td stylecode="Rrule">Combining saquinavir/ritonavir with nelfinavir is not recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">HIV-1 protease inhibitor:</content>
<br/>Tipranavir/ritonavir<footnoteref idref="tb3ft1"></footnoteref>
</td>
<td stylecode="Rrule">↓ Saquinavir<br/>
</td>
<td stylecode="Rrule">Combining saquinavir with tipranavir/ritonavir is not recommended. </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">HIV-1 CCR5 antagonist:</content>
<br/>Maraviroc</td>
<td stylecode="Rrule">↑ Maraviroc</td>
<td stylecode="Rrule">Maraviroc dose should be 150 mg twice daily when coadministered with INVIRASE/ritonavir. For further details see complete prescribing information for Selzentry<sup>®</sup> (maraviroc).<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="center" colspan="3" stylecode="Lrule Rrule">
<content stylecode="bold">Other Agents</content>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Ibutilide<br/>Sotalol</td>
<td stylecode="Rrule"></td>
<td stylecode="Rrule">Additive effects on QT and/or PR interval prolongation may occur with INVIRASE/ritonavir <content stylecode="italics">[see <linkhtml href="#S4">Contraindications (4)</linkhtml> and <linkhtml href="#S5.2">Warnings and Precautions (5.2,</linkhtml>
<linkhtml href="#S5.3"> 5.3)</linkhtml>]</content>. Coadministration of INVIRASE/ritonavir and ibutilide or sotalol is not recommended.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anticoagulant:</content>
<br/>Warfarin<footnoteref idref="tb3ft2"></footnoteref>
</td>
<td stylecode="Rrule">↑ Warfarin</td>
<td stylecode="Rrule">Concentrations of warfarin may be affected. It is recommended that INR (international normalized ratio) be monitored.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anticonvulsants:</content>
<br/>Carbamazepine<footnoteref idref="tb3ft2"></footnoteref>, phenobarbital<footnoteref idref="tb3ft2"></footnoteref>, phenytoin<footnoteref idref="tb3ft2"></footnoteref>
</td>
<td stylecode="Rrule">↓ Saquinavir<br/>
<br/>Effect on carbamazepine, phenobarbital, and phenytoin is not well established<br/>
</td>
<td stylecode="Rrule">Saquinavir may be less effective due to decreased saquinavir plasma concentrations in patients taking these agents concomitantly. Coadministration is not recommended. </td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Anti-gout:</content>
<br/>Colchicine</td>
<td stylecode="Rrule">↑ Colchicine</td>
<td stylecode="Rrule">
<content stylecode="underline">Treatment of gout flares-coadministration of colchicine in patients on INVIRASE/ritonavir:</content>
<br/>
<br/>0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (half tablet) 1 hour later. Dose to be repeated no earlier than 3 days.<br/>
<br/>
<content stylecode="underline">Treatment of familial Mediterranean fever (FMF) coadministration of colchicine in patients on INVIRASE/ritonavir:</content>
<br/>
<br/>Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day).<br/>
<br/>
<content stylecode="underline">Prophylaxis of gout-flares-co-administration of colchicine in patients on INVIRASE/ritonavir:</content>
<br/>
<br/>If the original colchicine regimen was 0.6 mg twice a day, the regimen should be adjusted to 0.3 mg once a day.<br/>
<br/>If the original colchicine regimen was 0.6 mg once a day, the regimen should be adjusted to 0.3 mg once every other day.<br/>
<br/>Patients with renal or hepatic impairment should not be given colchicine with INVIRASE/ritonavir.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Streptogramin antibiotics (quinupristin/dalfopristin<footnoteref idref="tb3ft2"></footnoteref>)</td>
<td stylecode="Rrule">Streptogramin antibiotics such as quinupristin/dalfopristin inhibit CYP3A4; saquinavir concentrations may be increased</td>
<td stylecode="Rrule">Monitoring for saquinavir toxicity is recommended. Use with caution due to possible cardiac arrhythmias.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">Fusidic acid</td>
<td stylecode="Rrule">↑ Saquinavir <br/>↑ Fusidic Acid <br/>↑ Ritonavir</td>
<td stylecode="Rrule">Concomitant use of fusidic acid and INVIRASE/ritonavir is not recommended due to potential for increased mutual toxicities. <br/>   <br/>The interaction between INVIRASE/ritonavir and fusidic acid has not been formally evaluated. Co-administration of fusidic acid and INVIRASE/ritonavir can cause increased plasma concentrations of fusidic acid, saquinavir and ritonavir.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antifungal:</content>
<br/>Ketoconazole<footnoteref idref="tb3ft1"></footnoteref>, <br/>itraconazole<footnoteref idref="tb3ft2"></footnoteref>
</td>
<td stylecode="Rrule">↔ Saquinavir<br/>↔ Ritonavir<br/>↑ Ketoconazole</td>
<td stylecode="Rrule">When INVIRASE/ritonavir and ketoconazole are coadministered, plasma concentrations of ketoconazole are increased (see <content stylecode="bold">
<linkhtml href="#table6">Table 6</linkhtml>
</content>). Hence, doses of ketoconazole or itraconazole &gt;200 mg/day are not recommended.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antimycobacterial:</content>
<br/>Rifabutin<footnoteref idref="tb3ft1"></footnoteref>
</td>
<td stylecode="Rrule">↔ Saquinavir<br/>↑ Rifabutin<br/>↔ Ritonavir<br/>
<br/>
</td>
<td stylecode="Rrule">No dose adjustment of INVIRASE/ritonavir (1000/100 mg bid) is required if  INVIRASE/ritonavir is administered in combination with rifabutin.<br/>
<br/>Dosage reduction of rifabutin by at least 75% of the usual dose of 300 mg/day is recommended (i.e., a maximum dose of 150 mg every other day or three times per week). Increased monitoring for adverse events including neutropenia and liver enzyme levels is warranted in patients receiving the combination.<br/>
<br/>Consider monitoring rifabutin concentrations to ensure adequate exposure.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Antipsychotic:</content>
<br/>Quetiapine</td>
<td stylecode="Rrule">↑ Quetiapine</td>
<td stylecode="Rrule">
<content stylecode="underline">Initiation of INVIRASE with ritonavir in patients taking quetiapine:</content>
<br/>Consider alternative antiretroviral therapy to avoid increases in quetiapine drug exposures. If coadministration is necessary, reduce the quetiapine dose to 1/6 of the current dose and monitor for quetiapine-associated adverse reactions. Refer to the quetiapine prescribing information for recommendations on adverse reaction monitoring.<br/>
<br/>
<content stylecode="underline">Initiation of quetiapine in patients taking INVIRASE with ritonavir:</content>
<br/>Refer to the quetiapine prescribing information for initial dosing and titration of quetiapine.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Benzodiazepines</content>
<footnoteref idref="tb3ft2"></footnoteref>
<content stylecode="bold">:</content>
<br/>Alprazolam, clorazepate, diazepam, flurazepam<br/>
</td>
<td stylecode="Rrule">↑ Benzodiazepines</td>
<td stylecode="Rrule">Clinical significance is unknown. Careful monitoring of patients for benzodiazepine effects is warranted; a decrease in benzodiazepine dose may be needed.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Benzodiazepine</content>
<footnoteref idref="tb3ft2"></footnoteref>
<content stylecode="bold">:</content>
<br/>Intravenously administered Midazolam</td>
<td stylecode="Rrule">↑ Midazolam</td>
<td stylecode="Rrule">If INVIRASE/ritonavir is coadministered with parenteral midazolam, close clinical monitoring for respiratory depression and/or prolonged sedation should be exercised and dosage adjustment should be considered.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Calcium channel blockers</content>
<footnoteref idref="tb3ft2"></footnoteref>
<content stylecode="bold">:</content>
<br/>Diltiazem, felodipine, nifedipine, nicardipine, nimodipine, verapamil, amlodipine, nisoldipine, isradipine<br/>
</td>
<td stylecode="Rrule">↑ Calcium channel blockers</td>
<td stylecode="Rrule">Caution is warranted and clinical monitoring of patients is recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Corticosteroid:</content>
<br/>Dexamethasone<footnoteref idref="tb3ft2"></footnoteref>
</td>
<td stylecode="Rrule">↓ Saquinavir<br/>
</td>
<td stylecode="Rrule">INVIRASE/ritonavir may be less effective due to decreased saquinavir plasma concentrations. Coadministration is not recommended.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Digitalis Glycosides: </content>Digoxin<footnoteref idref="tb3ft1"></footnoteref>
</td>
<td stylecode="Rrule">↑ Digoxin<br/>
<br/>Increases in serum digoxin concentration were greater in female subjects as compared to male subjects when digoxin was coadministered with INVIRASE/ritonavir.<br/>
</td>
<td stylecode="Rrule">Caution should be exercised when INVIRASE/ritonavir and digoxin are coadministered; serum digoxin concentrations should be monitored and the dose of digoxin may need to be reduced when coadministered with INVIRASE/ritonavir.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Endothelin receptor antagonists:</content>
<br/>Bosentan</td>
<td stylecode="Rrule">↑ Bosentan</td>
<td stylecode="Rrule">
<content stylecode="underline">Coadministration of bosentan in patients on INVIRASE/ritonavir:</content>
<br/>
<br/>In patients who have been receiving INVIRASE/ritonavir for at least 10 days, start bosentan at 62.5 mg once daily or every other day based upon individual tolerability.<br/>
<br/>
<content stylecode="underline">Coadministration of INVIRASE/ritonavir in patients on bosentan:</content>
<br/>
<br/>Discontinue use of bosentan at least 36 hours prior to initiation of INVIRASE/ritonavir.<br/>
<br/>After at least 10 days following the initiation of INVIRASE/ritonavir, resume bosentan at 62.5 mg once daily or every other day based upon individual tolerability.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Inhaled beta agonist:</content>
<br/>Salmeterol</td>
<td stylecode="Rrule">↑ Salmeterol</td>
<td stylecode="Rrule">Concurrent administration of salmeterol with INVIRASE/ritonavir is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Inhaled/nasal steroids:</content>
<br/>Fluticasone<footnoteref idref="tb3ft2"></footnoteref>
<br/>Budesonide</td>
<td stylecode="Rrule">↑ Fluticasone</td>
<td stylecode="Rrule">Concomitant use of fluticasone propionate and INVIRASE/ritonavir may increase plasma concentrations of fluticasone propionate, resulting in significantly reduced serum cortisol concentrations.  Several cases of Cushing's disease associated with this interaction have been reported in the literature. Coadministration of fluticasone propionate and INVIRASE/ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. If the combination is nevertheless considered necessary, a dose reduction of fluticasone propionate with close monitoring of local and systemic effects is recommended.<br/>A switch to a corticosteroid which is not a substrate for CYP3A (e.g., beclomethasone) should be considered. In case of withdrawal of corticosteroids, progressive dose reduction may have to be performed over a longer period.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">HMG-CoA reductase inhibitors</content>
<footnoteref idref="tb3ft2"></footnoteref>
<content stylecode="bold">:</content>
<br/>Atorvastatin</td>
<td stylecode="Rrule">↑ Atorvastatin<br/>
</td>
<td stylecode="Rrule">Titrate atorvastatin dose carefully and use the lowest dose necessary; do not exceed atorvastatin 20 mg/day. Patients should be carefully monitored for signs and symptoms of myopathy (e.g., muscle weakness, muscle pain, rising creatine kinase).</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Immunosuppressants</content>
<footnoteref idref="tb3ft2"></footnoteref>
<content stylecode="bold">:</content>
<br/>Cyclosporine, rapamycin</td>
<td stylecode="Rrule">↑ Immunosuppressants</td>
<td stylecode="Rrule">Therapeutic concentration monitoring is recommended for immunosuppressant agents when coadministered with INVIRASE/ritonavir.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Narcotic analgesic:</content>
<br/>Methadone<footnoteref idref="tb3ft1"></footnoteref>
</td>
<td stylecode="Rrule">↓ Methadone</td>
<td stylecode="Rrule">Dosage of methadone may need to be increased when coadministered with INVIRASE/ritonavir.<br/>
<br/>Use with caution. Additive effects on QT and/or PR interval prolongation may occur with INVIRASE/ritonavir <content stylecode="italics">[see <linkhtml href="#S4">Contraindications (4)</linkhtml> and <linkhtml href="#S5.2">Warnings and Precautions (5.2,</linkhtml>
<linkhtml href="#S5.3"> 5.3)</linkhtml>]</content>.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Oral contraceptives:</content>
<br/>Ethinyl estradiol<footnoteref idref="tb3ft2"></footnoteref>
</td>
<td stylecode="Rrule">↓ Ethinyl estradiol</td>
<td stylecode="Rrule">Alternative or additional contraceptive measures should be used when estrogen-based oral contraceptives and INVIRASE/ritonavir are coadministered.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">PDE5 inhibitors (phosphodiesterase type 5 inhibitors):</content>
<br/>Sildenafil<footnoteref idref="tb3ft1"></footnoteref>, vardenafil<footnoteref idref="tb3ft2"></footnoteref>, tadalafil<footnoteref idref="tb3ft2"></footnoteref>
</td>
<td stylecode="Rrule">↑ Sildenafil<br/>↔ Saquinavir<br/>
<br/>↑ Vardenafil<br/>↑ Tadalafil<br/>
<br/>Only the combination of sildenafil with saquinavir soft gelatin capsules has been studied at doses used for treatment of erectile dysfunction.<br/>
</td>
<td stylecode="Rrule">May result in an increase in PDE5 inhibitor-associated adverse events, including hypotension, syncope, visual disturbances, and priapism.<br/>
<br/>
<content stylecode="underline">Use of PDE-5 inhibitors for pulmonary arterial hypertension (PAH):</content>
<list listtype="unordered">
<item>Use of sildenafil (Revatio) is contraindicated when used for the treatment of pulmonary arterial hypertension (PAH) <content stylecode="italics">[see <linkhtml href="#S4">Contraindications (4)</linkhtml>]</content>.</item>
</list>   							The following dose adjustments are recommended for use of tadalafil (Adcirca<sup>®</sup>) with INVIRASE/ritonavir:<br/>
<br/>
<content stylecode="underline">Coadministration of Adcirca in patients on INVIRASE/ritonavir:</content>
<br/>
<br/>In patients receiving INVIRASE/ritonavir for at least one week, start Adcirca at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability.<br/>
<br/>
<content stylecode="underline">Coadministration of INVIRASE/ritonavir in patients on Adcirca:</content>
<br/>
<br/>Avoid use of Adcirca during the initiation of INVIRASE/ritonavir. Stop Adcirca at least 24 hours prior to starting INVIRASE/ritonavir. After at least one week following the initiation of INVIRASE/ritonavir, resume Adcirca at 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability.<br/>
<br/>
<content stylecode="underline">Use of PDE5 inhibitors for erectile dysfunction:</content>
<br/>
<br/>Use sildenafil with caution at reduced doses of 25 mg every 48 hours with increased monitoring of adverse events when administered concomitantly with INVIRASE/ritonavir.<br/>
<br/>Use vardenafil with caution at reduced doses of no more than 2.5 mg every 72 hours with increased monitoring of adverse events when administered concomitantly with INVIRASE/ritonavir.<br/>
<br/>Use tadalafil with caution at reduced doses of no more than 10 mg every 72 hours with increased monitoring of adverse events when administered concomitantly with INVIRASE/ritonavir.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Tricyclic antidepressants</content>
<footnoteref idref="tb3ft2"></footnoteref>
<content stylecode="bold">: </content>Amitriptyline, clomipramine, imipramine, maprotiline</td>
<td stylecode="Rrule">↑ Tricyclics</td>
<td stylecode="Rrule">Therapeutic concentration monitoring is recommended for tricyclic antidepressants when coadministered with INVIRASE/ritonavir.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Other antidepressants:</content>
<br/>Nefazodone</td>
<td stylecode="Rrule">↑ Saquinavir </td>
<td stylecode="Rrule">Monitoring for saquinavir toxicity is recommended.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Proton pump inhibitors: </content>Omeprazole<footnoteref idref="tb3ft1"></footnoteref>
</td>
<td stylecode="Rrule">↑ Saquinavir</td>
<td stylecode="Rrule">When INVIRASE/ritonavir is co-administered with omeprazole, saquinavir concentrations are increased significantly.  If omeprazole or another proton pump inhibitor is taken concomitantly with INVIRASE/ritonavir, caution is advised and monitoring for potential saquinavir toxicities is recommended, particularly gastrointestinal symptoms, increased triglycerides, deep vein thrombosis, and QT prolongation.<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Herbal Products:</content>
<br/>St. John's wort<footnoteref idref="tb3ft2"></footnoteref> (hypericum perforatum)</td>
<td stylecode="Rrule">↓ Saquinavir</td>
<td stylecode="Rrule">Herbal products containing St. John's wort should not be used concomitantly with INVIRASE/ritonavir because coadministration may lead to loss of virologic response and possible resistance to INVIRASE or to the class of protease inhibitors.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Other drugs that are substrates of CYP3A: </content>
<br/>Fentanyl<footnoteref idref="tb3ft2"></footnoteref>
<br/>Alfentanil<footnoteref idref="tb3ft2"></footnoteref>
</td>
<td stylecode="Rrule">↑ Fentanyl<br/>↑ Alfentanil</td>
<td stylecode="Rrule">Coadministration with these drugs may accentuate the side effects reported with use of fentanyl or alfentanil including respiratory depression, apnea and bradycardia.</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule">
<content stylecode="bold">Vasodilators (peripheral):</content>
<br/>Intravenously administered Vincamine</td>
<td stylecode="Rrule">↑ Vincamine</td>
<td stylecode="Rrule">Monitoring for vincamine toxicity is recommended. Use with caution due to potential cardiac arrhythmias.</td>
</tr>
<tr>
<td stylecode="Lrule Rrule">Garlic Capsules<footnoteref idref="tb3ft2"></footnoteref>
</td>
<td stylecode="Rrule">↓ Saquinavir</td>
<td stylecode="Rrule">Coadministration of garlic capsules and saquinavir is not recommended due to the potential for garlic capsules to induce the metabolism of saquinavir which may result in sub-therapeutic saquinavir concentrations.<br/>
</td>
</tr>
</tbody>
</table>